Navigation Links
Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
Date:1/28/2009

Stock to trade under new ticker symbol 'CDXP.OB'

LA JOLLA, Calif., Jan. 28 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) announced today that it has completed a corporate name change to Cordex Pharma, Inc. As a result of the name change, the Over-the-Counter Bulletin Board will trade the Company's common stock under the ticker symbol OTCBB: CDXP.OB.

James S. Kuo, M.D., Cordex's Chief Executive Officer commented, "We are pleased to have completed our corporate name change and selected a new ticker symbol. The Cordex name was chosen for two primary reasons. First, 'cor' is the Latin word for heart, which is the focus of our drug development efforts. Second, Cordex is an intentional derivation of 'codex', the Latin word for book. Before printing presses, handwritten codices were the repository of all human knowledge. Through our two late-stage clinical programs, we intend to write a new chapter in the development of proprietary pharmaceuticals that treat urgent medical needs."

In addition to the name change and new ticker symbol, Cordex announced several other corporate changes. The Company has appointed MorisonCogen, LP of Bala Cynwyd, PA, as its independent auditors for the year ending December 31, 2008. Cordex also appointed DirectTransfer, LLC as its stock transfer agent, effective immediately.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex is developing a portfolio of investigational medicines, two of which are in late stages of clinical trials. Cordex's AT
'/>"/>

SOURCE Duska Therapeutics, Inc.; Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
(Date:10/22/2014)... , Oct. 21, 2014   BioNano Genomics ... latest genomics research centers to purchase an ... the National Cancer Institute (NCI), NIH Intramural Sequencing ... Before Irys, obtaining a comprehensive view of a ... sequencing (NGS) does not deliver the scalability or ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... ImmusanT, Inc. announced today it has raised ... Healthcare Partners LLC to advance development of the ... monitoring tool for celiac disease. The proceeds will ... to the point of demonstrating proof-of-concept. ImmusanT expects ...
... Dec. 13, 2011 IRIDEX Corporation (Nasdaq: IRIX ... for Health and Clinical Excellence (NICE) has issued a ... is not as cost effective as conventional laser photocoagulation ... treatment for diabetic macular edema (DME), a swelling of ...
Cached Medicine Technology:ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease 2ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease 3UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema 2UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema 3
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... length may be showing a genetic propensity for obesity as ... have been linked to increased body fat, but the same ... muscle, the researchers said. At 1 year, kids with ... and 3, however, these genes were linked to excessive weight ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Parker Named Interim Chief Financial Officer , , ... MDTH ), a healthcare provider focused on high ... cardiovascular disease, today announced that Art Parker, Senior Vice ... Financial Officer. Parker replaces Jeff Hinton, whose employment ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it will ... 10, 2009 at 4:30 pm Eastern Time. Dave Holveck, President and ... programs. , , The presentation will be webcast live and can ... the investors section. , , About Endo ...
... Scientists make strides in finding ways to slow tumor ... A protein called PHD2 that regulates blood vessel growth ... researchers who analyzed levels of the protein in tumor ... expression of PHD2, researchers at Stanford University School of ...
... CORAL GABLES, FL (June 5, 2009)--Dengue Fever (DF) and ... viral diseases in the World. Around 50-100 million cases ... of suffering this debilitating and sometimes fatal disease. Dengue ... an interdisciplinary team of researchers from the University of ...
... Interleukin Genetics, Inc. (NYSE Amex: ... President of Research and Development, will present findings that ... to weight-loss in overweight individuals at the American Diabetes ... Aziz will present the Company,s research at 8 a.m. ...
... --- Neighborhoods with restaurants, entertainment, cultural facilities and ethnic ... Chicago than neighborhoods where residents are less likely to ... facilities. , Published in the spring 2009 ... Immunology , the two-year study led by Ruchi Gupta, ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference 2Health News:Researchers develop the first climate-based model to predict Dengue fever outbreaks 2Health News:Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 2Health News:Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 3Health News:Asthma rates and where you live 2
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: